Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with MTX and TNF Inhibitors in RA
NCT00298272Phase 2Terminated
- Sponsor
- Biogen
- Start
- May 2006
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rituximab Arm with Placebo Arm (2 arms). Primary endpoints: Proportion of Participants With at Least One Serious Infection at 24 weeks, Number of Participants With Any Infections or Any Grade 3/4 Infections at 24 weeks and 3 more. Started May 2006; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00298272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298272.